ライフサイエンスコーパス: low molecular weight

1 r into a moderate PI3Kalpha inhibitor with a low molecular weight.

2 ect exchange of intracellular molecules with low molecular weights.

3 trated that our method could detect HCP with low molecular weight (11 kDa and 17 kDa) at a concentrat

4 llows the direct detection of bisphenol A, a low molecular weight (228 Da) target usually detectable

5 Experimental results evidenced that low molecular weight (50-190 kDa) chitosan can be used t

6 S100 family genes encode low molecular weight, acidic-Ca(2+) binding proteins imp

7 itively regulated by adjusting the dose of a low molecular weight adapter that must bridge between th

8 eaction to a variety of organic materials or low molecular weight agents that are present in the work

9 te-specific membrane antigen (PSMA)-targeted low-molecular-weight agents for (212)Pb-based TRT of pat

10 In particular, low-molecular-weight aggregates of the Alzheimer amyloid

11 tem, which showed improved responsivities to low molecular weight alcohols compared to similar sensor

12 The resulting low molecular weight alginates were investigated by UV-v

13 des, lipids, lignin, carbohydrates, and some low-molecular-weight aliphatic and aromatic compounds) a

14 e of atmospheric organic nitrogen, including low molecular weight alkyl-amines.

15 approaches in investigating the mechanism of low-molecular-weight amyloid inhibitors.

16 mpounds would be an ideal tool for screening low-molecular weight analytes (<2000 Da) having many var

17 rations of thrombin (10(-18) m) as well as a low molecular weight anatoxin (165 Da, 10(-14) m) are de

18 isomerization in heptane and a PAO show that low molecular weight and oligomeric carboxylic acids are

19 ead of Tau pathology, and by virtue of their low molecular weight and relative solubility, oligomers

20 Frankia CcI3 supernatant are hydrophilic, of low molecular weight and resistant to chitinase degradat

21 Low molecular weight AR species were nuclear localized a

22 rapolating from lessons learnt with previous low-molecular-weight beta-(1->3)-glucan mimetics, we des

23 statistical differences have been found for low-molecular-weight biocompounds, PEGs, and nonhydropho

24 Here, we utilized a cocktail of low-molecular-weight bispecific adapters, each comprised

25 employment of independent variables such as low molecular weight carbohydrates (LMWC), soluble solid

26 Several low-molecular-weight carbohydrates exhibit the same effe

27 stead, fragmentation produces polyfunctional low molecular weight carboxylic acids after oxidative cl

28 eptor-targeted radiopharmaceuticals based on low-molecular-weight carriers offer many clinically adva

29 The export of low-molecular-weight catabolic end-products is facilitat

30 ria, fungi, animal proteins, plant proteins, low molecular weight chemicals, and metals.

31 Low-molecular-weight chemicals that likely derive from b

32 Low molecular weight chitosan exerted a potent inhibitor

33 an un-supplemented state is associated with low molecular weight circulating metabolites.

34 The addition of low molecular-weight co-pigments such as gallic acid and

35 A series of low-molecular-weight, compact, and multifunctional cycli

36 nalyses was used to determine changes in the low-molecular-weight compound composition of peanuts due

37 sly, we synthesized a beta-particle-emitting low-molecular-weight compound, (177)Lu-L1 which demonstr

38 s able to detect low submicrogram amounts of low molecular weight compounds (<500 Da).

39 most efficient method in terms of yields of low molecular weight compounds (in particular chlorogeni

40 ion, and decarboxylation, and (ii) releasing low molecular weight compounds and inorganic nutrients f

41 ed drug design exploits initial screening of low molecular weight compounds and their concomitant aff

42 even quantify the minute amounts of secreted low molecular weight compounds produced by living and is

43 By contrast, analysis of low molecular weight compounds with this technique has b

44 in juices was five times lower than that of low molecular weight compounds, while the transfer of hi

45 ancers, in particular blocking Siglec-7 with low molecular weight compounds.

46 ate a particularly high capacity for loading low-molecular weight compounds and even folded proteins.

47 olomics to perform quantitative profiling of low-molecular weight compounds from biological specimens

48 MS was found to provide enhanced coverage of low-molecular weight compounds such as amino acids, wher

49 Our efforts yielded low-molecular weight compounds that bind TAR with low mi

50 ve targeting of biological macromolecules by low-molecular weight compounds.

51 fermentation, with a concurrent increase in low-molecular-weight compounds (hydroxybenzoic and hydro

52 ignificant impact on the levels and types of low-molecular-weight compounds present.

53 In a phenotypic screen seeking low-molecular-weight compounds that protected beta-cells

54 oduced for measuring the binding kinetics of low-molecular-weight compounds to their biomolecular tar

55 ponsible for chain transfer and formation of low molecular weight copolymers in the traditional catal

56 nitrification, is prone to the production of low-molecular-weight dissolved organic N (LMW-DON), whic

57 ainly glutathione disulfide (GSSG) and other low-molecular-weight disulfides.

58 easily included to modulate the transport of low molecular weight drug-like entities through the netw

59 olecular therapeutics that avoids the use of low molecular weight drugs.

60 udomonas aeruginosa quorum-sensing-regulated low-molecular-weight excreted molecule, triggers autolys

61 Tumours in mice genetically deficient in low-molecular weight FGF2 (FGF2(LMW)) regress dependent

62 Obesity increased BBB permeability to the low molecular weight fluorophore sodium fluorescein (NaF

63 ytes, JARID2 predominantly exists as a novel low molecular weight form, which lacks the N-terminal PR

64 Low molecular weight fraction had the highest umami inte

65 e digest showed that the iron was present in low molecular weight fractions which contained glucose,

66 naptotoxic activities were found in high and low molecular weight fractions.

67 IP) to identify and map the binding sites of low molecular weight fragments that engage RNA or Chem-C

68 such as HYAL-1 resulting in pro-inflammatory low-molecular weight fragments.

69 kinetics, but only one of the formulations (low molecular weight, free acid terminated) exhibited th

70 ructure on supramolecular gels, we combine a low-molecular-weight gelator (LMWG) with the polymer gel

71 hydrogel in situ based on Schiff base 2 as a low-molecular-weight gelator (LMWG).

72 tly affect the properties of a solution of a low-molecular-weight gelator at high pH.

73 The low-molecular-weight gelator DBS is thus a low-cost addi

74 Hydrogels formed by the self-assembly of low-molecular-weight gelators (LMWGs) are promising scaf

75 he addition of gluten, glutenin and purified low molecular weight glutenin subunits (LMW-GS) using a

76 t in a single wheat line lowered gliadin and low-molecular-weight glutenin accumulation by 50% to 60%

77 tion of extracellular HA and accumulation of low molecular weight HA (LMW-HA) in tumor tissue was ass

78 While low molecular weight HA increases sensitivity to mechani

79 this study, we screened several inexpensive, low-molecular-weight haloalkanes as blocking agents in p

80 to potable quality have difficulty removing low molecular weight halogenated disinfection byproducts

81 The low molecular weight hapten, Ochratoxin A (OTA), is a na

82 The development of antibodies to low molecular weight haptens remains challenging due to

83 Low molecular weight heparin (LMWH) in therapeutic doses

84 We hypothesized that low molecular weight heparin (LMWH) is superior to unfra

85 agulants (DOACs) may be good alternatives to low molecular weight heparin (LMWH) or vitamin K antagon

86 Low molecular weight heparin (LMWH; standard prophylacti

87 eatments included substitution of heparin or low-molecular weight heparin for warfarin (n = 13 [72%])

88 nous thromboembolism previously treated with low-molecular weight heparin, fondaparinux, or a vitamin

89 ts did not differ from that with warfarin or low-molecular-weight heparin (factor Xa vs warfarin IRR

90 ned to receive either a prophylactic dose of low-molecular-weight heparin (for the 8 days after arthr

91 We have shown previously that the GAG low-molecular-weight heparin (LMWH) binds to Abeta40 fib

92 ada, since 2006, involved replacing UFH with low-molecular-weight heparin (LMWH) for prophylactic and

93 with a higher risk of bleeding compared with low-molecular-weight heparin (LMWH) in patients with GI

94 partum period is not above a threshold where low-molecular-weight heparin (LMWH) prophylaxis is clear

95 K antagonist (VKA) throughout pregnancy; 2) low-molecular-weight heparin (LMWH) throughout pregnancy

96 is of randomized controlled trials comparing low-molecular-weight heparin (LMWH) vs no LMWH in women

97 ic thromboprophylaxis with unfractionated or low-molecular-weight heparin (pneumatic compression grou

98 vs dabigatran 0.88 [0.59-1.36]; factor Xa vs low-molecular-weight heparin 1.02 [0.42-2.70]; and low-m

99 Anticoagulants, primarily low-molecular-weight heparin and warfarin, are used to t

100 that compared direct oral anticoagulant with low-molecular-weight heparin are also summarised, along

101 d with hydroxychloroquine, azithromycin, and low-molecular-weight heparin at anticoagulant dose.

102 r than conventional anticoagulation therapy (low-molecular-weight heparin followed by vitamin K antag

103 oral anticoagulant compared with warfarin or low-molecular-weight heparin for all indications.

104 tal venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followe

105 s of our trials showed that prophylaxis with low-molecular-weight heparin for the 8 days after knee a

106 icoagulants have been recently compared with low-molecular-weight heparin for the management of acute

107 dditional clinical trials of edoxaban versus low-molecular-weight heparin for the treatment of venous

108 Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thr

109 of 10 431 participants; 4139 included in the low-molecular-weight heparin group and 4139 in the contr

110 58 (4.0%) of 3958 with available data in the low-molecular-weight heparin group compared with 279 (7.

111 the control population and 88 (2.1%) in the low-molecular-weight heparin group, and minor bleeding e

112 roup and 652 (16.6%) of 3937 patients in the low-molecular-weight heparin group.

113 Low-molecular-weight heparin is the standard treatment f

114 bivalirudin monotherapy vs unfractionated or low-molecular-weight heparin plus optional GPIs (control

115 monotherapy compared with unfractionated or low-molecular-weight heparin plus optional GPIs on 1-yea

116 Low-molecular-weight heparin reduces risk of venous thro

117 lecular-weight heparin 1.02 [0.42-2.70]; and low-molecular-weight heparin vs dabigatran 0.67 [0.20-1.

118 itial treatment with unfractionated heparin, low-molecular-weight heparin, or fondaparinux, usually o

119 Therapy with low-molecular-weight heparin, vitamin K antagonists, and

120 now prefer full-dose oral Xa inhibitors over low-molecular-weight heparin, with gastrointestinal lesi

121 s (97%), of whom 600 (89%) were treated with low-molecular-weight heparin.

122 ral anticoagulants compared with warfarin or low-molecular-weight heparin.

123 th direct oral anticoagulants, warfarin, and low-molecular-weight heparin.

124 ral anticoagulants compared with warfarin or low-molecular-weight heparin.

125 ypercoagulable state, which was treated with low-molecular-weight heparin.

126 Vitamin K antagonists or low molecular weight heparins are still alternatives to

127 in binding of various glycosaminoglycans and low molecular weight heparins by microscale thermophores

128 Historically, in patients with cancer, low molecular weight heparins have been preferred for tr

129 ompared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWHs) in these patients.

130 Standard of care (low-molecular-weight heparins, unfractionated heparin, v

131 We use this approach to detect low molecular weight HT-2 toxins (crucial for food safet

132 Low molecular weight hyaluronan (LMWH) acts at both pept

133 cumulation of inflammatory and proangiogenic low molecular weight hyaluronan fragments.

134 It behaves as a highly efficient low-molecular-weight hydrogelator with an extremely low

135 as universal dispersing agents in water for low-molecular-weight hydrophobes.

136 erface and by targeting the interface with a low molecular weight inhibitor, we show that TNFalpha re

137 successful, structure-guided development of low molecular weight inhibitors specifically and selecti

138 acologically more favorable approaches using low-molecular-weight inhibitors has been hampered by low

139 y used as alternate matrices to minimize the low molecular weight interferences observed in typical M

140 MALDI imaging mass spectrometry (IMS) of low molecular weight ions is particularly challenging as

141 Purpose To synthesize two low-molecular-weight iron chelates and compare their T1

142 ore, intact G1/S transition (Rb-positive and low-molecular-weight isoform of cyclin E (cytoplasmic)-n

143 ange -2.5) and concomitant increase in their low molecular weight isoforms (mean fold-change 6.4 and

144 The iron chelator-loaded low-molecular-weight keratin hydrogel with quick degrada

145 variants progressively yielded smaller-sized low-molecular-weight levans, as the affected subsites th

146 rinsic fluorescence and loss of binding of a low-molecular weight ligand.

147 elative to other proteins, nucleic acids and low molecular-weight ligands.

148 Methods: Five rationally designed low-molecular-weight ligands (L1-L5) were synthesized us

149 e model allowing us to assemble a library of low-molecular-weight ligands predicted to bind the SAS-6

150 in labile pools, defined as loosely bound to low-molecular-weight ligands, which can regulate diverse

151 iety from a UDP-sugar cofactor to relatively low-molecular weight lipophilic compounds.

152 o clad conventional monofilament fibers with low-molecular-weight liquid crystals (LCs) stabilized by

153 in high yields (up to 80 weight percent) to low-molecular-weight liquid/wax products, in the absence

154 in (Ig)-E in occupational asthma (OA) due to low molecular weight (LMW) agents is not well establishe

155 However, for low molecular weight (LMW) allergens, pooled sensitivity

156 Characterizing low molecular weight (LMW) dissolved organic matter (DOM

157 nvestigate the persistence of (14)C-labelled low molecular weight (LMW) DOC at a wide range of concen

158 Low molecular weight (LMW) forms and monomers were the m

159 n of Maillard reaction (MR), induced between low molecular weight (LMW) peptides and sucrose, was stu

160 Compromise of this pathway results in low molecular weight (LMW) proteinuria that can progress

161 Mycothiol (MSH) is the major low molecular weight (LMW) thiol in Actinomycetes.

162 ns, associates with an elevated abundance of low molecular weight (LMW) thiols, including glutathione

163 antigen had a small molecular size [25 kDa, low molecular weight (LMW)].

164 Hs that are considerably more toxic than the low molecular weight (LMW, 2-3 ring) PAHs.

165 LABs were used to produce breads from which low molecular weight (LMW-) peptides were extracted.

166 Most of the abundant PAHs identified were low molecular weight (LMW-PAH) (liver > muscle) with 2-3

167 ct that was then fractionated for elution of low-molecular weight (LMW) and high-molecular weight (HM

168 The effect of addition of the low-molecular weight (LMW) organic compounds, easily ion

169 Low-molecular weight (LMW) phthalate diesters function a

170 t into the periplasm, such that little to no low-molecular weight (LMW) products are externally relea

171 Low-molecular-weight (LMW) and high-molecular-weight (HM

172 High-molecular-weight (HMW) proteins and low-molecular-weight (LMW) chemicals can cause occupatio

173 and the commonly administered anticoagulant, low-molecular-weight (LMW) heparin, in the initiation an

174 on of S-nitrosothiols, including protein and low-molecular-weight (LMW) S-nitrosothiols (S-nitroso-GS

175 activated without apparent dissociation into low-molecular-weight (LMW) species after RNase A treatme

176 ly the nonconserved Cys-127 reacted with the low-molecular-weight (LMW) thiol mycothiol, protecting i

177 Here we identify such a low-molecular-weight (LMW)-dT source as mostly dTDP-gluc

178 scavenge the blood pool and surface-capture low-molecular-weight, low-abundance plasma proteins that

179 Here, we present the proteome profiling of low-molecular weight (<50 kDa) proteins of seven differe

180 viral ligand polyinosinic-polycytidylic acid-low-molecular-weight/LyoVec and LPS to evaluate IFN-alph

181 Low molecular weight metabolites are essential for defin

182 Here, we use MALDI timsTOF IMS to image low molecular weight metabolites at higher spatial resol

183 this improved sensitivity, we have found >40 low molecular weight metabolites in human kidney tissue,

184 relation between sweat and blood considering low-molecular weight metabolites is even better than tha

185 The analysis of low-molecular-weight metabolites by new high-throughput

186 Of the 51 lipids, fatty acids, and low-molecular-weight metabolites, 21 were significantly

187 bolite measures: 51 lipids, fatty acids, and low-molecular-weight metabolites; 98 lipid composition a

188 rious binding events, particularly involving low molecular weight molecules.

189 e-radical polymerization of water-insoluble, low-molecular-weight monomers that show a large change i

190 organically bound iodine (org-(129)I) with a low molecular weight (MW) range (0.5-5 kDa) in all soils

191 he R(ee) landscape by measuring P(R(ee)) for low molecular weight (MW: 0.22-2.6 kDa) dilute PEO chain

192 ics that may be poorly removed by RO include low-molecular weight (MW) neutral compounds.

193 A low-molecular-weight (MW) model study shows that these m

194 These results establish the advantage of low molecular weight, narrow polydispersity, and amorpho

195 mpetitive immunoassays, for the detection of low molecular weight natural toxicants, as an alternativ

196 a model, batch FO experiments concluded that low molecular weight neutral compound transfer is depend

197 mbrane process that can selectively separate low molecular weight neutral compounds such as ammonia f

198 aimed to determine the transport behavior of low molecular weight neutral nitrogen compounds in order

199 ntaminants and the insufficient rejection of low-molecular-weight neutral organics by RO calls for th

200 coefficients by fragmenting the structure of low-molecular-weight neutral organics into small parts t

201 mall molecules and antibodies by combining a low molecular weight of about 2 kDa with an antibody-lik

202 depth of the SAR, as well as the relatively low molecular weight of the series, suggests, but does n

203 cape model, we predict the structures of the low-molecular weight oligomeric form and the dynamics of

204 led to their quantitative dissociation into low molecular weight oligomers ( approximately 8-70 kDa)

205 into low molecular weight species, and these low molecular weight oligomers are significantly more bi

206 Low molecular weight oligomers of amyloid-beta (Abeta) h

207 This method enables access to low molecular weight oligomers, and molecular weights be

208 n states, which result from the formation of low molecular weight oligomers, high molecular weight ol

209 Abeta aggregates, especially the low-molecular weight oligomers, are the primary toxic ag

210 The latter leads for Abeta (1-40) to low-molecular-weight oligomers only, which is in contras

211 This results in soluble low-molecular-weight oligomers that can act as a therape

212 s the purification and the identification of low molecular weight oligosaccharides contained in an Et

213 Low molecular weight organic acids (LMWOAs) represent th

214 A general overview on low molecular weight organic chemistry is given, and the

215 nt kingdom produces hundreds of thousands of low molecular weight organic compounds.

216 lved organic matter (DOM) into inorganic and low-molecular-weight organic products, contributing to i

217 A small library of 57 low molecular weight oximes was prepared from fragrant a

218 We report a functionally unique family of low-molecular-weight PBPs that act as transpeptidases ra

219 ses that form peptidoglycan cross-links, and low-molecular-weight PBPs, which are typically hydrolase

220 el and convenient approach to generate ultra-low molecular weight pectin with high efficiency and hig

221 dings indicate that precise modifications of low molecular weight PEI improve its bio-responsiveness

222 w value source to produce highly digestible, low molecular weight peptide powders that could be used

223 rance of globular proteins and generation of low molecular weight peptides (less than 3kDa).

224 seed expeller demonstrated an enrichment of low molecular weight peptides (molecular weight <15 kDa)

225 PsaI represents one of three low molecular weight peptides of PSI.

226 are homotetrameric, alpha-helical bundles of low-molecular-weight peptides.

227 ptor, revealing MPST's potential to generate low-molecular-weight persulfides.

228 However, as opposed to conventional low molecular weight pesticides, the environmental fate

229 Low molecular weight phenolic compounds (LMWPC), includi

230 ated DI (RDI) and one sustained (SDI) on the low molecular weight phenolics together with the antioxi

231 gation revealed differential accumulation of low-molecular-weight phenolics, including (glycosylated)

232 s study aims to investigate the stability of low molecular weight phlorotannin fractions from Fucus v

233 their cognate histidine kinases but also by low molecular weight phosphodonors such as acetyl phosph

234 er prenatal concentrations of metabolites of low-molecular weight phthalates (SigmaLMW) were associat

235 core [e.g., B per 10-fold increase in summed low-molecular weight phthalates = - 1.7 (95% CI: - 3.1,

236 temperature and pH) to reduce gallic acid, a low molecular weight pigment (MW 170gmol(-1)) widely fou

237 an efficient method to reduce the potential low molecular weight pigment present in the sugarcane.

238 extend our previous work on phosphorescent, low molecular weight platinum(II) complex as an oxygen s

239 n particulate matter (PM) and the associated low molecular weight polycyclic aromatic hydrocarbons (P

240 (Ad-SS-GD) with beta-cyclodextrin-conjugated low-molecular-weight polyethyleneimime (CP) through supr

241 Conversely, extraction with KOH 25% provided low molecular weight polysaccharides with substantially

242 The use of KOH 2% increased the amount of low molecular weight polysaccharides, resulting in bimod

243 in amino acids and nucleobases into a single low molecular weight precision polyamide polymer.

244 Ibbeta3 mAb fused to a thrombin-activatable, low-molecular-weight pro-uPA (PLT/uPA-T).

245 The low molecular weight protein tyrosine phosphatase (LMW-P

246 3 distinct protease activities in the LMP2 (low-molecular-weight protein 2), LMP7 (low-molecular-wei

247 LMP2 (low-molecular-weight protein 2), LMP7 (low-molecular-weight protein 7), and MECL1 (multicatalyt

248 growth medium demonstrated the presence of a low molecular weight proteinaceous secreted factor that

249 -IR) spectroscopy to detect and quantify the low-molecular-weight proteinaceous components of blood s

250 time-of flight (TOF) proteomics to identify low molecular weight proteins that associated with poor

251 ght proteins and correlated only weakly with low molecular weight proteins, suggestive of tubular pro

252 ricity and present massive urinary losses of low-molecular-weight proteins and albumin, caused by sel

253 These low-molecular-weight proteins are relatively freely filt

254 result in the production and accumulation of low-molecular-weight proteins in the urine and systemic

255 concentrations of amino acids, peptides, and low-molecular-weight proteins present in serum samples.

256 of glucosuria, phosphaturia, aminoaciduria, low molecular weight proteinuria, and albuminuria.

257 l Ocrl-knockout mouse background resulted in low molecular weight proteinuria, phosphaturia, and acid

258 (PT) dysfunction typically characterized by low molecular weight proteinuria, renal tubular acidosis

259 ensive overview of the current literature on low-molecular-weight PSMA ligands for both PET imaging a

260 Investigations on the reactivity of low-molecular-weight quinones, which are believed to be

261 bifunctional catalysts for the conversion of low-molecular-weight reactants.

262 rease the efficacy and clinical potential of low-molecular-weight, receptor-targeted agents.

263 e broadly, this work suggests that flexible, low-molecular-weight sequence-defined polymers can serve

264 s and evaluation of the first, high-affinity low molecular weight Siglec-7 ligands to interfere with

265 cal pretreatments to extract and concentrate low molecular weight SMPs (MW< 580 Da) from effluents we

266 iols (SNOs) in proteins and small molecules (low-molecular-weight SNOs) whose levels are regulated by

267 The results suggest that low molecular weight species (peak 6), related to the ir

268 Low molecular weight species (peak 9), related to the ph

269 technology is generally limited to releasing low molecular weight species that can diffuse through th

270 the abundant HMW oAbeta can dissociate into low molecular weight species, and these low molecular we

271 valent polymer or a noncovalent aggregate of low molecular weight species.

272 n a significant level of cardiac TnT and the low molecular weight splice form of ssTnT.

273 ain a significant level of cardiac TnT and a low molecular weight splice form of ssTnT.

274 of essential elements present in the form of low-molecular weight stable complexes known for their bi

275 mers are rationally designed from relatively low-molecular-weight starting materials, with the degree

276 bstrate-based approach to the development of low molecular weight STEP inhibitors with Ki values as l

277 gradation of acrylamide (AA), asparagine and low molecular weight sugars were evaluated during an ind

278 structure, reported for the self-assembly of low molecular weight surfactants, for example, lipids, b

279 Low molecular weight synthetic peptides have been demons

280 s have largely focused on the development of low-molecular-weight, synthetic BH3 mimetics ("magic bul

281 A "fragment hit", a molecule of low molecular weight that has been validated to bind to

282 Haptens are small molecules with low molecular weight that include biotin and many toxins

283 Because of ease of synthesis and low molecular weight, the conjugate base of triethylurea

284 is mainly buffered by bacillithiol (BSH), a low molecular weight thiol.

285 between a protein cysteine and an attacking low molecular-weight thiol have a dramatic effect on the

286 that reported for the reaction with the main low-molecular-weight thiol in M. tuberculosis, mycothiol

287 E-SSH could transfer its sulfane sulfur to a low-molecular-weight thiol, a process likely facilitated

288 GSH is a low-molecular-weight thiol-containing tripeptide (l-gamm

289 k, we examined the reactions of NO2-CLA with low molecular weight thiols (glutathione, cysteine, homo

290 lated and S-cysteinylated peptides, in which low molecular weight thiols are attached to cysteine res

291 7 cells, including elevated abundance of the low molecular weight thiols coenzyme A (CoA) and glutath

292 osylation of cysteine thiols in proteins and low molecular weight thiols such as GSH.

293 chemical mechanisms of peroxide reduction by low molecular weight thiols, Prxs, GPxs, and other thiol

294 trisulfide can transfer allyl side chains to low molecular weight thiols.

295 lar bioavailability to Hg(II) complexes with low-molecular-weight thiols.

296 ry clearance.Methods: The effects of a novel low-molecular-weight TMEM16A potentiator (ETX001) were e

297 Low molecular weight, uncharged compounds have been the

298 ng of free PAI-1 and complexes of PAI-1 with low-molecular-weight urokinase-type plasminogen activato

299 mers (-9+/-1%, P<0.0001) and accumulation of low-molecular-weight vWF multimers (+40+/-5%, P<0.0001)

300 Today, low-molecular-weight Y(4)R ligands are lacking, in parti